{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-010220","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.000905+00:00","generated_at":"2026-06-17T02:08:29.973498+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SAB Biotherapeutics receives FDA Fast Track Designation for SAB-176 influenza immunotherapy for high-risk patients","bullets":["Fast Track Designation granted for SAB-176, an investigational therapeutic for Type A and B influenza in high-risk patients, including those with antiviral-resistant strains.","FDA aligned on Phase 2b trial design evaluating safety and efficacy in high-risk patients; manufacturing approach also aligned.","SAB-176 is a fully-human polyclonal IgG antibody produced without human donors via the DiversitAb platform.","Phase 2a data showed broad cross-protection against multiple influenza strains, including non-targeted strains.","The designation enables frequent FDA interactions, priority review, and rolling review eligibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-010220","json":"https://secwatch.observer/filing/0001437749-23-010220.json","markdown":"https://secwatch.observer/filing/0001437749-23-010220.md","text":"https://secwatch.observer/filing/0001437749-23-010220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923010220/0001437749-23-010220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923010220/sabs20230413_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:08:29.973498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}